Aminalonum

For treatment of: Aminalonum nootropic nervous system, brain.

Aminalonum nootropics

For the treatment of internal organs: nervous system, brain
Appointment: prevention of motion sickness, alcoholic polyneuropathy, post-stroke conditions, traumatic brain injury, encephalopathy, cerebrovascular insufficiency, mental retardation in children, cerebral palsy, prevention of kinetosis
Indications for use:
Residual effects of traumatic brain injury, stroke; cerebrovascular insufficiency, encephalopathies of various origins, alcoholic encephalopathy, alcoholic polyneuropathy, cerebral palsy, consequences of traumatic brain birth trauma in children older than 3 years, mental retardation, symptoms of motion sickness (sea and air sickness).
Contraindications:
Hypersensitivity to the components of the drug, children under 3 years of age, acute renal failure, sucrose/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption, celiac disease.
Composition:
1 tablet of the drug contains the active substance: gamma-aminobutyric acid - 250,000 mg, excipients: sucrose (white sugar) - 27,200 mg, magnesium stearate - 2,800 mg, shell: opadray 200 white (polyvinyl alcohol - 4,900 mg, titanium dioxide - 3,500 mg, macrogol (polyethylene glycol) - 1,680 mg, talc - 3,343 mg, methacrylic acid copolymer type C - 0,560 mg, sodium bicarbonate - 0,017 mg) - 14,000 mg.
Manufacturer: Organika